Iran resumed its missile production after it received a chemical shipment from China carrying the main precursor in the ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

Older adults in England reported better mental well-being after the pandemic, but also slightly elevated depression rates. View on euronews ...

With its flattering rhetoric, leniency in responding to US trade threats and alignment with Washington this week at a summit ...

Talks cement a relationship between UEFA, Europe’s leading clubs and an agency that wants to stage European club football in ...

Where the travel editors and experts are going in 2025 Haven’t decided where to go this year? Let our in-the-know editors and most widely travelled experts inspire you ...

Research suggests arts and cultural engagement can be used to help treat the symptoms of a number of conditions, including ...

China is facing a demographic time bomb. Its population shrank for the third straight year in 2024, putting it on course for a "Japanification" in which the old vastly outnumber the working-age ...

The main international forum for drumming up weapons and ammunition for Ukraine will for the first time meet under the ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...